Histogen to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Histogen Inc. (NASDAQ: HSTO) has announced that its CEO, Richard W. Pascoe, will present at the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Histogen Inc. (NASDAQ: HSTO) has announced that its CEO, Richard W. Pascoe, will present at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021. The presentation will be available on-demand starting at 7:00 AM ET. Histogen focuses on developing innovative restorative therapeutics that aim to stimulate the body's natural repair processes. Their technology includes cell-conditioned media and extracellular matrix materials aimed at treating various conditions such as joint cartilage and soft tissue repair.
Details
News Market Reaction – HSTO
The recorded move for HSTO in the trading session of this news was +3.78%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Aug. 31, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today announced that Richard W. Pascoe, President and Chief Executive Officer of Histogen, will present at the H.C. Wainwright 23rd Annual Global Investment Conference.
Presentation Details
The presentation will be available for on-demand listening beginning Monday, September 13, 2021 at 7:00 AM Eastern Time and can be accessed using the link https://journey.ct.events/view/c065249e-2ede-44de-ad16-38ecae89a28d.
About Histogen Inc.
Histogen Inc. is a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function. Histogen’s innovative technology platform utilizes cell conditioned media and extracellular matrix materials produced by hypoxia-induced multipotent cells. Histogen’s proprietary, reproducible manufacturing process provides targeted solutions across a broad range of therapeutic indications, including joint cartilage regeneration, spinal disk repair, tendon, ligament and other soft tissue repair. For more information, please visit www.histogen.com.
CONTACT:
Susan A. Knudson
Executive Vice President & CFO
Histogen Inc.
ir@histogen.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.